Clinical Trial: Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More

U.S., May 3 -- ClinicalTrials.gov registry received information related to the study (NCT06954818) titled 'Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More' on April 24.

Brief Summary: Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. This randomized, observer-blind, placebo-controlled, adaptive phase 1 trial aims to evaluate the safety and immunogenicity of an investigational zoster mRNA vaccine in healthy participants aged 40 years...